Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMXT 1501

Drug Profile

AMXT 1501

Alternative Names: AMX-1501; AMX-513; AMX513 dicaprate; AMXT 1501 dicaprate; AMXT1501

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aminex Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunostimulants; Polyamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase 0 Glioma

Most Recent Events

  • 11 Oct 2023 Preclinical data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 21 Apr 2023 Aminex completes phase-I trial in Solid tumours(Combination therapy, In children, In adults, In adolescents, In the elderly, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03536728)
  • 01 Mar 2023 Phase-0 for Glioma (Combination therapy, Late-stage disease) in USA (Intratumoural) (NCT05717153)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top